Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2024; 30(43): 4660-4668
Published online Nov 21, 2024. doi: 10.3748/wjg.v30.i43.4660
Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function
Yu-Qi Sun, Yang Wu, Meng-Ran Li, Yu-Yao Wei, Mei Guo, Zi-Li Zhang
Yu-Qi Sun, Yang Wu, Meng-Ran Li, Yu-Yao Wei, Mei Guo, Zi-Li Zhang, Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China
Co-corresponding authors: Mei Guo and Zi-Li Zhang.
Author contributions: Sun YQ, Li MR, Wei YY, Guo M, and Zhang ZL contributed to this paper; Zhang ZL designed the overall concept and outline of the manuscript; Guo M and Sun YQ contributed to the discussion and design of the manuscript; Sun YQ, Wu Y, Li MR, and Wei YY contributed to the writing, and editing the manuscript, illustrations, and review of literature; Guo M and Zhang ZL contributed equally to this work as co-corresponding authors; and all authors have read and approved the final manuscript.
Supported by the National Natural Science Foundation of China, No. 82474164, No. 82305046, and No. 82000572; Natural Science Foundation of Jiangsu Province, No. BK20220467; Major Project of the Natural Science Research of Jiangsu Higher Education Institutions, No. 22KJB310013; and Science and Technology Project of Jiangsu Province, No. BK20200840.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zi-Li Zhang, MD, PhD, Professor, Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, No. 138 Xianlin Avenue, Nanjing 210023, Jiangsu Province, China. zilizhang@njucm.edu.cn
Received: July 26, 2024
Revised: September 29, 2024
Accepted: October 18, 2024
Published online: November 21, 2024
Processing time: 97 Days and 7.6 Hours
Core Tip

Core Tip: Peroxisome proliferator-activated receptor (PPAR) can inhibit the pathological process of alcohol-related liver disease (ALD). However, the dual PPARα/δ agonist elafibranor has been studied mainly in metabolic dysfunction-associated steatohepatitis and primary cholangitis, and its role in ALD and its mechanism need to be further explored.